Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Dec;7(6):452-457.
doi: 10.1007/s12975-016-0490-6. Epub 2016 Aug 12.

Recent Advances in Stem Cell-Based Therapeutics for Stroke

Affiliations
Editorial

Recent Advances in Stem Cell-Based Therapeutics for Stroke

Eleonora Napoli et al. Transl Stroke Res. 2016 Dec.

Abstract

Regenerative medicine for central nervous system disorders, including stroke, has challenged the non-regenerative capacity of the brain. Among the many treatment strategies tailored towards repairing the injured brain, stem cell-based therapeutics have been demonstrated as safe and effective in animal models of stroke, and are being tested in limited clinical trials. We address here key lab-to-clinic translational research that relate to efficacy, safety, and mechanism of action underlying stem cell therapy. Recognizing the multi-pronged cell death processes associated with stroke that will likely require combination therapies, we next discuss potent drugs and novel technologies directed at improving the functional outcomes of stem cell-based therapeutics. We also examine discrepant transplant regimens between preclinical studies and clinical trials, as well as missing appropriate control arm (i.e., stroke subjects undergoing rehabilitation) on which to directly compare the therapeutic benefits of cell therapy. Finally, the bioethics of cell therapy is presented in order to assess its prevailing social status. With preliminary results now being reported from on-going clinical trials of stem cell therapy for stroke, a careful assessment of the true functional benefits of this novel treatment will further direct the future of regenerative medicine for neurological disorders.

PubMed Disclaimer

Conflict of interest statement

CVB received research grants from NIH, NeuralStem, Karyopharm, SanBio Inc, and has patent applications related to stem cell therapy with Athersys Inc and SanBio Inc. EN declares that she has no conflict of interest.

Similar articles

Cited by

References

    1. Muotri AR, Gage FH. Generation of neuronal variability and complexity. Nature. 2006;441:1087–93. - PubMed
    1. Lindvall O, Kokaia Z. Stem cells for the treatment of neurological disorders. Nature. 2006;441:1094–6. - PubMed
    1. Androutsellis-Theotokis A, Leker RR, Soldner F, Hoeppner DJ, Ravin R, Poser SW, et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature. 2006;442:823–6. - PubMed
    1. Chen J, Venkat P, Zacharek A, Chopp M. Neurorestorative therapy for stroke. Front Hum Neurosci. 2014;8:382. - PMC - PubMed
    1. Boltze J, Lukomska B, Jolkkonen J, consortium M-I Mesenchymal stromal cells in stroke: improvement of motor recovery or functional compensation? J Cereb Blood Flow Metab. 2014;34:1420–1. - PMC - PubMed

Publication types